再鼎醫藥(09688.HK)將於8月8日發佈中期業績
格隆匯7月27日丨再鼎醫藥(09688.HK)公佈,董事會審核委員會將於2023年8月8日(星期二,香港時間)審議及批准(其中包括)根據美國公認會計准則("美國公認會計准則")及美國證券交易委員會("美國證交會")的適用規則編制的截至2023年6月30日止三個月及六個月的未經審核中期業績("業績")及其發佈。
倘獲批准,公司將於2023年8月8日(星期二,香港時間)在香港聯合交易所有限公司網站www.hkexnews.hk 及公司網站www.zailaboratory.com 發佈業績。
在業績獲批准及發佈後,公司管理層計劃在2023年8月8日(星期二,香港時間)下午八時正舉行現場業績電話會議及網絡直播,以討論業績並回答問題。有意參與人士可透過本公司網站 http://ir.zailaboratory.com 收聽現場網絡直播。所有參與者均須於電話會議開始前透過下文提供的連結完成線上登記流程。登記後,各參與者將收到一封內含撥號詳情的確認電郵。
登記連結: https://register.vevent.com/register/BIb7d99f107c3347f29e117b2b7bc47034
電話會議後,將於短時間內提供重播,並可透過訪問公司網站 http://ir.zailaboratory.com收聽重播。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.